Battling the hematological malignancies: the 200 years' war

Area of Science:

• Hematology
• Oncology
• Cancer Research

Background:

• The study traces the historical development of understanding and treating hematological malignancies, starting from the 19th century with Hodgkin's disease.
• It highlights the evolution from early radiation therapy to the current use of over 50 drugs across 14 classes, including targeted agents.

Observation:

• Despite significant advancements, including cures for certain childhood leukemias and lymphomas, the majority of patients with blood cancers still experience poor prognoses and reduced lifespans.
• Key challenges include the lack of identifiable external causes, age-related incidence and treatment efficacy decline, the vast number of disseminated cancer cells including stem cells, and the genetic heterogeneity of these diseases.

Findings:

• Current treatments, while effective for some, face limitations due to redundant cancer cell survival pathways and the increasing cost and specificity of drug development.
• Long-term adverse effects of therapies on both pediatric and adult patients remain a significant concern.

Implications:

• Future progress hinges on fostering novel collaborations between academia, industry, and government.
• Expanding international research participation and securing governmental commitment to cancer research funding are crucial for overcoming existing hurdles and improving patient outcomes.